Abstract:Bone is an estradiol-responsive tissue. Estrogen withdrawal during the menopause causes loss of bone mass and clinically relevant osteoporosis in a third of all women. Sufficient or impaired local production, as well as degradation of estradiol in cells present in the bone microenvironment might be an important mechanism of rescue or might contribute to the development of osteoporosis, respectively. We therefore investigated aromatase and 17beta-hydroxysteroid dehydrogenase type IV (17beta-HSD IV) expression in osteoblast- and osteoclast-like cells. Aromatase mRNA was increasingly expressed in myeloid THP 1 cells differentiated along the monocyte/phagocyte pathway exploiting vitamin D and either granulocyte-macrophage-stimulating factor (GMCSF) or macrophage-stimulating factor (MCSF). In long-term cultures, when sequentially exposed to vitamin D (days 0-21) and GMCSF (days 5-10) and plated on collagen, the amount of expression of aromatase mRNA steadily increased along with the increasing expression of osteopontin mRNA, alpha(v) integrin mRNA, c-fms (MCSF-receptor) mRNA and multinucleated cells developing. The conversion of estradiol from testosterone (10(-7) M/l) in the supernatants of dishes mirrored changes in aromatase mRNA expression and by day 21 rose to 30,000 ng/10(7) cells/24 h. 17Beta-HSD IV mRNA expression was abundant in undifferentiated THP 1 cells and was decreased to approximately 50% by day 21. Unstimulated SV-40 immortalized fetal osteoblasts did not express aromatase mRNA, but the expression was stimulated by the addition of the phorbol ester phorbol myristate acetate (PMA). Unstimulated osteoblasts from primary cultures did not express aromatase mRNA. Osteoblast-like osteosarcoma cells MG 63 expressed faint levels of aromatase mRNA in contrast to the osteosarcoma cell line HOS 58. 17Beta-HSD IV mRNA was expressed in fetal osteoblasts as well as in osteoblasts from primary culture, MG 63 and HOS 58 cells. In summary, we can show the expression of estradiol metabolizing enzymes in cells which are present in the bone microenvironment. Impaired aromatase expression and/or enhanced expression of 17beta-HSD IV may contribute to the pathogenesis of osteoporosis.

Steroid hormone metabolizing enzymes in benign and malignant human bone tumors

Molecular Mechanisms of Estrogen Receptor Β-Induced Apoptosis and Autophagy in Tumors: Implication for Treating Osteosarcoma

The Sulfatase Pathway for Estrogen Formation: Targets for the Treatment and Diagnosis of Hormone-Associated Tumors

Steroid metabolism and hormonal dynamics in normal and malignant ovaries

Local estradiol metabolism in osteoblast- and osteoclast-like cells

Estrogen and bone metabolism in man]

De novo steroidogenesis in tumor cells drives bone metastasis and osteoclastogenesis

Metastatic bone disease: Pathogenesis and therapeutic options

Aromatase activity and bone loss

Steroid Sulfation in Adrenal Tumors

Steroid sulfatase and sulfotransferases in the estrogen and androgen action of gynecological cancers: current status and perspectives

Steroids and Malignancy Increase Local Heparanase and Decrease Markers of Osteoblast Activity in Bone Tissue Microcirculation

Aromatase mutation in men as a rare cause of osteoporosis: a case report and review of the literature

Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management

Bone-Targeted Therapies in Cancer-Induced Bone Disease

Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology

Steroid sulfatase inhibitors: the current landscape

The osteoblast in regulation of tumor cell dormancy and bone metastasis

Mechanisms of sexual dimorphism in the pathogenesis of sarcomas

Regulation of Stromal Cells by Sex Steroid Hormones in the Breast Cancer Microenvironment

Mechanisms, Diagnosis and Treatment of Bone Metastases